Paydirt
RB
Insider

Rebecca Byam

Chief Financial Officer

Rebecca Byam (Chief Financial Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in HCW Biologics Inc. (HCWB). Across 1 priced purchase filing, the average 21-session return was -13.7% from execution and -25.1% from disclosure (delay-adjusted; derived). The largest single filing was $220K of HCWB (8,462 sh × $26.00, as filed), executed May 8 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-13.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-25.1%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$220K
shares × price, as filed
Last traded
May 8 2025
Filed May 9 2025
Open performance
Volume by month
$220K$110K$0Oct 2024Apr 2025Oct 2025Apr 2026May 2025 · buys $220K
Buys $220K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 24 months

Most traded names
HCWB HCW Biologics Inc. HCWB · 1 buy · 0 sells 1 filing
Recent filings
HCWBPURCHASE HCW Biologics Inc. View filing → $220K
8,462 sh × $26.00
Exec May 8 2025
Filed May 9 2025 · 5:30 PM ET